TY - JOUR
T1 - Targeting protein kinases for the treatment of glioblastoma multiforme
T2 - Linking basic studies to clinical applications
AU - Zhou, Aidong
N1 - Funding Information:
I really thank Prof. Suyun Huang in the Department of Neurosurgery of UT MD Anderson Cancer Center for her kind suggestion to the manuscript and support to the project. This work was supported by National Institutes of Health/National Cancer Institute R01 grant (1R01CA182684).
Publisher Copyright:
© 2017 Bentham Science Publishers.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults with intensive heterogeneity and one of the most lethal human cancers. Protein kinases control diverse cellular processes by coordinating different signaling pathways. Protein kinases are frequently dysregulated in human cancers, which contributes to tumor initiation and development. Thus, protein kinases are a growing drug target class for cancers including glioblastoma. This review focuses on the most important protein kinases and kinase-mediated signaling cascades in glioblastoma, and discusses the functional mechanism of these kinases in glioblastoma tumorigenesis. Moreover, this review has summarized the most recent preclinical and clinical advances of agents targeting protein kinases in the treatment of glioblastoma.
AB - Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults with intensive heterogeneity and one of the most lethal human cancers. Protein kinases control diverse cellular processes by coordinating different signaling pathways. Protein kinases are frequently dysregulated in human cancers, which contributes to tumor initiation and development. Thus, protein kinases are a growing drug target class for cancers including glioblastoma. This review focuses on the most important protein kinases and kinase-mediated signaling cascades in glioblastoma, and discusses the functional mechanism of these kinases in glioblastoma tumorigenesis. Moreover, this review has summarized the most recent preclinical and clinical advances of agents targeting protein kinases in the treatment of glioblastoma.
KW - Clinical trials
KW - Combination treatment
KW - Glioblastoma
KW - Inhibitor
KW - Protein kinase
KW - Therapeutic strategy
UR - http://www.scopus.com/inward/record.url?scp=85038878859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038878859&partnerID=8YFLogxK
U2 - 10.2174/1381612823666170710144325
DO - 10.2174/1381612823666170710144325
M3 - Review article
C2 - 28699529
AN - SCOPUS:85038878859
SN - 1381-6128
VL - 23
SP - 4290
EP - 4302
JO - Current pharmaceutical design
JF - Current pharmaceutical design
IS - 29
ER -